AstraZeneca studies find Seroquel effective adjunct in depression treatment

By Elaine Rigoli

Tampa, Fla., May 22 - AstraZeneca announced results of two clinical studies that examined Seroquel (quetiapine fumarate) in combination with antidepressant therapy in patients with depression.

One study evaluated the use of Seroquel in combination with antidepressant therapies to improve residual depressive and anxiety symptoms in patients with major depressive disorder.

The study found significant reduction in several rating scales as early as week 1 and continuing through week eight, according to a news release.

The second study examined the benefit of Seroquel when added to SSRI/SNRI therapies in patients with treatment-resistant depression.

The second trial, also a randomized, double-blind, placebo-controlled trial, found that at the end of the eight-week trial, patients receiving Seroquel demonstrated a response to treatment of 67% versus 27%, the release said.

AstraZeneca is a global pharmaceutical company based in Wilmington, Del.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.